Log in to search using one of your social media accounts:

 

pH - Balanced Vaginal Gel Doesn ’ t Improve Dyspareunia
No difference versus placebo for sexual function, frequency of sexual dysfunction for breast cancer survivors (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 8, 2017 Category: Cancer & Oncology Tags: Family Medicine, Gynecology, Nursing, Oncology, Pharmacy, Journal, Source Type: news

Shares fall after trial fail for Juniper Pharmaceuticals
Shares of Boston-based women ’s health biotech Juniper Pharmaceuticals sank after the company announced that a gel hoped to reduce pain in women during an endometrial biopsy failed a mid-stage trial. The news sent shares of the company down 24 percent to $5.38 — its lowest point in more than a year — as of 11:30 a.m. Ju niper’s (Nasdaq: JNP) Phase 2b clinical trial tested its 10 percent lidocaine bioadhesive vaginal gel, COL-1077, for the reduction of pain intensity. But Juniper said late… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 18, 2016 Category: Pharmaceuticals Authors: Don Seiffert Source Type: news

Can HRT in early menopause cut heart disease risk?
ConclusionThis double-blind RCT found that women taking HRT less than six years after the menopause had slower artery wall thickening than those taking a placebo. This represented the main measure of atherosclerosis progression tested; other measures showed no difference, so the results were not as conclusive as they could have been. Women taking HRT 10 or more years after menopause also showed no difference in atherosclerosis progression compared with a placebo, further complicating the picture.An important limitation of this study is the lack of a patient relevant endpoint, such as cardiovascular events or mortality. Pre...
Source: NHS News Feed - April 1, 2016 Category: Consumer Health News Tags: Heart/lungs Medication Source Type: news

Tenofovir Vaginal Gel Cuts Herpes Risk (CME/CE)
(MedPage Today) -- Protection with pericoital gel increased with adherence (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - August 7, 2015 Category: Infectious Diseases Source Type: news

South Africa: Vaginal Gel Fails to Protect Against HIV Despite Earlier Trial
[Health-e]In a blow for HIV prevention, a vaginal gel that showed some effect against HIV in an earlier trial has failed to protect women in a big follow-up trial. (Source: AllAfrica News: HIV-Aids and STDs)
Source: AllAfrica News: HIV-Aids and STDs - February 25, 2015 Category: Infectious Diseases Source Type: news

Final results of the HIV prevention study VOICE are published in NEJM
(Microbicide Trials Network) Researchers who conducted the VOICE study involving more than 5,000 women in Africa detail in the NEJM how none of the products (tenofovir, Truvada and tenofovir vaginal gel) was effective in preventing HIV and the extent that women did not use them. Tests of blood indicate nonuse began early; many women never used the products. Yet, among women in the tenofovir gel group whose blood tests indicated use, HIV risk was reduced by 66 percent. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - February 4, 2015 Category: Infectious Diseases Source Type: news

Vaginal gel as good as shots for IVF: study
NEW YORK (Reuters Health) - Pregnancy outcomes don’t differ among women who use a vaginal hormone gel during in vitro fertilization or a hormone shot, according to a new study. (Source: Reuters: Health)
Source: Reuters: Health - June 5, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

Actavis And Valeant Announce FDA Approval For Metronidazole
Actavis and Valeant Pharmaceuticals announced in a press release that the Food and Drug Administration (FDA) has approved Metronidazole 1.3% Vaginal Gel. The approved New Drug Application (NDA) is for an antibiotic to treat bacterial vaginosis (BV). (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - April 7, 2014 Category: Pharmaceuticals Source Type: news

US FDA approves Actavis-Valeant's NDA for Metronidazole 1.3% vaginal gel
The US Food and Drug Administration (FDA) has approved Actavis-Valeant's new drug application (NDA) for Metronidazole 1.3% vaginal gel, an antibiotic for treatment of bacterial vaginosis (BV). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 27, 2014 Category: Pharmaceuticals Source Type: news

Rwanda: The Gel Is Not a Magic Bullet to HIV Prevention
[New Times]LAST week US scientists released research findings indicating that they had developed new vaginal gel that could help protect women from contracting HIV/Aids. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - March 18, 2014 Category: African Health Source Type: news

HIV Prevention Gel Shows Promise
Researchers are a step closer to developing a vaginal gel that could protect women against HIV, according to a study published in Science Translational Medicine, though scientists admit more testing is necessary. The difference between this study and others on prevention gels? This gel was applied and tested after sex. A team of U.S. researchers found that the gel protected five out of six monkeys from an animal-human laboratory strain of HIV when applied shortly before or up to three hours after infection, the BBC reported. Since the drug has the potential to work after HIV exposure, the findings could lead to new ways t...
Source: TIME: Top Science and Health Stories - March 13, 2014 Category: Science Authors: Francesca Trianni Tags: Uncategorized Aids HIV study Source Type: news

Even hours after sex, new vaginal gel could protect women against HIV
A research team, led by investigators from the Centers for Disease Control and Prevention, has developed a new vaginal gel that they say could protect women from HIV, even if it is applied hours after sex.This is according to a study recently published in the journal Science Translational Medicine.In the past, scientists have developed microbicides - gels that can kill or neutralize viruses and bacteria - containing antiretroviral drugs to protect against HIV (human immunodeficiency virus) transmission. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 13, 2014 Category: Consumer Health News Tags: HIV / AIDS Source Type: news

Vaginal Gel Might Prevent HIV Hours After Exposure
Title: Vaginal Gel Might Prevent HIV Hours After ExposureCategory: Health NewsCreated: 3/12/2014 2:36:00 PMLast Editorial Review: 3/13/2014 12:00:00 AM (Source: MedicineNet HIV General)
Source: MedicineNet HIV General - March 13, 2014 Category: Infectious Diseases Source Type: news

Vaginal Gel Might Prevent HIV Hours After Exposure
Lab tests with monkeys look promising, study says (Source: WebMD Health)
Source: WebMD Health - March 12, 2014 Category: Consumer Health News Source Type: news

Gel Protects Monkeys From H.I.V. After Sex, Study Finds
The vaginal gel worked even three hours after exposure, which would be particularly useful for women affected by domestic violence and rape.     (Source: NYT Health)
Source: NYT Health - March 12, 2014 Category: Consumer Health News Authors: By DONALD G. McNEIL Jr. Tags: Centers for Disease Control and Prevention Drugs (Pharmaceuticals) Acquired Immune Deficiency Syndrome Source Type: news

Vaginal Gel Might Prevent HIV Hours After Exposure
Lab tests with monkeys look promising, study says Source: HealthDay Related MedlinePlus Pages: HIV/AIDS in Women, Sexual Health, Sexually Transmitted Diseases (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - March 12, 2014 Category: Consumer Health News Source Type: news

Vaginal Gel Might Prevent HIV Hours After Exposure
Lab tests with monkeys look promising, study says (Source: Fertility News - Doctors Lounge)
Source: Fertility News - Doctors Lounge - March 12, 2014 Category: Reproduction Medicine Authors: webmaster at doctorslounge.com Tags: Gynecology, Infections, AIDS, Reproductive Medicine, Research, News, Source Type: news

CONRAD wins USAID Science and Technology Pioneers Prize for development of first vaginal gel proven to reduce HIV
(CONRAD) CONRAD, a leading reproductive health-research organization based at Eastern Virginia Medical School, today announced that they are a winner of the United States Agency for International Development Science and Technology Pioneers Prize for their work in developing tenofovir gel. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - January 29, 2014 Category: Infectious Diseases Source Type: news

Actavis Acquires Worldwide Rights for Valeant's Metronidazole 1.3% Vaginal Gel
PARSIPPANY, N.J., and MONTREAL, May 1, 2013 -- (Healthcare Sales & Marketing Network) -- Actavis, Inc. (ACT), and Valeant Pharmaceuticals International, Inc. (VRX) (VRX) today announced that Actavis Specialty Brands (the "Company") has acquired ... Biopharmaceuticals, AcquisitionsValeant Pharmaceuticals, Actavis, Metronidazole (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 1, 2013 Category: Pharmaceuticals Source Type: news

Actavis buys antibiotic vaginal gel from Valeant for $55 million
(Reuters) - Generic drugmaker Actavis Inc bought the global rights to Canadian firm Valeant Pharmaceuticals International Inc's antibiotic vaginal gel for about $55 million. (Source: Reuters: Health)
Source: Reuters: Health - May 1, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

Bee Venom Destroys HIV And Spares Surrounding Cells
Nanoparticles containing bee venom toxin melittin can destroy human immunodeficiency virus (HIV) while at the same time leaving surrounding cells unharmed, scientists from Washington University School of Medicine reported in the March 2013 issue of Antiviral Therapy. The researchers said that their finding is a major step toward creating a vaginal gel that can prevent HIV spread. HIV is the virus that causes AIDS. Joshua L... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 10, 2013 Category: Consumer Health News Tags: HIV / AIDS Source Type: news

Study of tenofovir vaginal gel shows daily dosing ineffective due to lack of adherence
(CONRAD) Researchers with the Microbicide Trials Network today announced results of the Vaginal and Oral Interventions to Control the Epidemic study at the Conference for Retroviruses and Opportunistic Infections in Atlanta, Georgia. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - March 4, 2013 Category: Global & Universal Source Type: news

The 30-year fight against HIV
Since its identification as the cause of Aids in 1984, scientists have made major advancements in tackling virus1984 Retrovirus is discovered as cause of Aids and later named human immunodeficiency virus or HIV.1986 Clinical trials show that HIV patients taking AZT (azidothymidine), an antiretroviral drug initially developed as a cancer therapy, were living longer than those who did not. AZT is shown to manage, but not cure, HIV and reduce the rates of mother-to-child infection in pregnancy.1987 The US FDA approves AZT as the first antiretroviral to be used as a treatment for Aids.1995 Jeff Getty, Aids activist, becomes th...
Source: Guardian Unlimited Science - March 3, 2013 Category: Science Authors: Caroline Davies Tags: The Guardian News Health Medical research Aids and HIV Society Source Type: news

Tenofovir Gel Wins Out In Drug Absorption Study, But HIV Prevention Trials Say Differently
A novel head-to-head study looking at differences in how the antiretroviral (ARV) drug tenofovir gets absorbed in the body as either an oral tablet or a vaginal gel found tenofovir gel can achieve substantially higher concentrations of active drug in vaginal tissue than the oral tablet, suggesting that tenofovir gel should be highly effective in protecting women against HIV transmitted through vaginal sex... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 1, 2013 Category: Consumer Health News Tags: HIV / AIDS Source Type: news

Tenofovir gel wins out in drug absorption study, but HIV prevention trials say differently
(Microbicide Trials Network) A study looking at how the body absorbs the antiretroviral drug tenofovir as either an oral tablet or a vaginal gel found the gel achieves much higher concentrations of active drug in vaginal tissue than the tablet, suggesting it to be highly effective in protecting against HIV through vaginal sex. But results of HIV prevention trials have shown differently, leading researchers to conclude that effectiveness of tenofovir products depends not just on tissue concentrations. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - January 30, 2013 Category: Infectious Diseases Source Type: news